Imbal hasil Treasury 10 tahun AS mencapai level tertinggi sejak 2007, memicu kekhawatiran akan kerentanan di sektor perumahan, properti komersial, dan perusahaan dengan utang besar. Para ahli memperingatkan bahwa dampak terburuk akan terasa dalam 12-18 bulan ke depan saat utang lama harus direfinansiasi dengan biaya yang jauh lebih tinggi. Sektor perumahan diperkirakan akan menjadi yang pertama merasakan dampaknya karena kenaikan suku bunga KPR akan memperburuk keterjangkauan dan membekukan aktivitas transaksi. Tekanan juga akan muncul pada perusahaan dan pemilik properti yang meminjam saat suku bunga rendah dan kini harus melakukan refinancing dengan biaya yang lebih tinggi.
Treasury yields hitting 5% has Pluang data as of Sep 16, 2026 10:01 WIB. Of 74 priced Financials-sector US stocks, 20 rose and 51 fell today. NDAQ traded at USD 89.49, a -2.27% change; MCO at USD 467.64, a -2.18% change; and FUTU at USD 108.69, a -2.18% change.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
